{"title":"Weight-loss drugs Ozempic and Wegovy also protect your heart","link":"https://arstechnica.com/?p=1965717","date":1694007776000,"content":"<div>\n<figure>\n  <img src=\"https://cdn.arstechnica.net/wp-content/uploads/2023/09/semaglutide-800x600.jpg\" alt=\"Injection pen\" />\n      <p><a href=\"https://cdn.arstechnica.net/wp-content/uploads/2023/09/semaglutide.jpg\">Enlarge</a> <span>/</span> An injection pen at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Monday, June 12, 2023.:  (credit: Carsten Snejbjerg/Bloomberg/Getty Images)</p>  </figure>\n\n\n\n\n\n\n<div><a name=\"page-1\"></a></div>\n<p>The benefits of the drug semaglutide, sold under the brand names Ozempic and Wegovy, seem to go beyond <a href=\"https://www.wired.com/story/ozempic-wegovy-quitting-weight-loss/\">controlling diabetes</a> and <a href=\"https://www.wired.com/story/obesity-drugs-researcher-interview-ozempic-wegovy/\">helping people shed pounds</a>. New research shows that the drug also has cardiovascular benefits and may lead to a better quality of life for people with heart problems who are also overweight.</p>\n<p>In a trial of more than 500 patients with obesity and heart failure in 13 countries, those who got a weekly injection of semaglutide over the course of a year reduced symptoms such as fatigue, shortness of breath, and swelling. They also had notable improvements in their physical abilities and exercise function. The findings were published in late August in the <a href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa2306963\">New England Journal of Medicine</a>.</p>\n<p>Heart failure is a condition in which the organ struggles to pump enough blood to meet the bodyâ€™s needs, because it is either too weak or not elastic enough. The patients in this study had a common type of heart failure in which the heart pumps normally but is too stiff to fill properly.</p></div><p><a href=\"https://arstechnica.com/?p=1965717#p3\">Read 18 remaining paragraphs</a> | <a href=\"https://arstechnica.com/?p=1965717&amp;comments=1\">Comments</a></p>","author":"WIRED","siteTitle":"Ars Technica","siteHash":"5b0ddf6e8923e49262a7894cfd77962733e43fbcc565a103b48373820b310636","entryHash":"e664fec7d662898d70ef265b44833f66bea0b8ac5e29b52a2568c8d762eacdc5","category":"Tech"}